Pliant Therapeutics (PLRX)

• Market cap: $93.9M
• 1 day: -3.77%
• 5 days: -10%
• 1 month: -1.29%
• 3 months: 12.5%
• 6 months: -10%
• Year to date: -88.48%
• 1 year: -87.11%
• 5 years: -94.11%
• 10 years: -92.82%
• Sector: Healthcare
• Industry: Biotechnology

About: Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Employees: 171

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

22% more call options, than puts

Call options by funds: $133K | Put options by funds: $109K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10.67% less ownership

Funds ownership: 94.53% [Q1] → 83.87% (-10.67%) [Q2]

19% less funds holding

Funds holding: 140 [Q1] → 114 (-26) [Q2]

23% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 39

24% less capital invested

Capital invested by funds: $78.5M [Q1] → $59.7M (-$18.8M) [Q2]

52% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 50

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4
• Avg. target: $4
• High target: $4

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Yasmeen Rahimi

$4

Overweight Maintained

8 Aug 2025